bioMérieux is a French company specializing in in vitro diagnostics, world leader in microbiology and agri-food applications, located near Lyon. BioMérieux offers solutions to determine the source of a disease or contamination. Its reagents, instruments and software are used in the diagnosis of infectious diseases for cardiovascular emergencies, screening and monitoring of cancers as well as for the detection of microorganisms in agri-food, pharmaceutical and cosmetic products.
The Mérieux family has more than a century of experience in biology and development of in vitro diagnostic tests. Marcel Mérieux was a student of Louis Pasteur. In 1897, he founded a medical analysis laboratory in Lyon which became the Institut Mérieux. It was in this laboratory that Marcel Mérieux developed the first anti-tetanus serums. In 1937, Marcel Mérieux's son, Doctor Charles Mérieux, took over the reins of the laboratory after his father's death. During the 1940s, he introduced a technique developed by the Dutchman Frenkel - in vitro culture - which transformed the manufacture of vaccines and led to the production of reagents for in vitro diagnostic tests. In 1963, Charles Mérieux's son, Alain Mérieux, created BD Mérieux, owned equally by the Institut Mérieux and Becton Dickinson, offering a wide range of products for medical analysis laboratories. When Alain Mérieux became the majority shareholder of BD Mérieux in 1974, the company took the name bioMérieux.
Over the past 40 years, bioMérieux has become an international group, a recognized player in the in vitro diagnostics sector. The fight against infectious diseases is at the heart of its development strategy and remains the group's primary mission. The microbiology market, in which bioMérieux holds a market share of 36.4% (of 1.85 billion dollars), is a relatively mature market with expected growth rates of only about 3-6% per year. bioMérieux has stated its intention to increase its presence in high-growth areas such as molecular biology, clinical testing, and theranostics (individually adapted treatment). The company competes with several companies in the diagnostics market, including Rock, Abbott Laboratories , Becton, Dickinson And JOHNSON & JOHNSON.
bioMérieux offers a average yield of 1.31%, which is certainly modest but covered by a distribution ratio very cautious of 23.70%. The dividend grows at an average annual rate of 5.22%. The liquidity ratio is good, with 1.48, as is the debt/equity ratio, with 0.15.
BIM has clearly beaten the CAC40 since 2005. The stock's volatility is a bit high, but remains affordable, with 15.27%. The beta of only 0.21 also indicates that the stock is not very sensitive to market variations.
One way bioMérieux plans to achieve growth is through the expansion and optimization of its sales force abroad. BioMérieux created a Global Business Operations Department to facilitate this expansion and chose the United States and Japan as target markets outside Europe through which it can expand. Today bioMérieux is present in more than 150 countries through 40 subsidiaries and a large network of distributors. This diversified presence abroad allows the stock to be well hedged against dollar risk, with a $risk of -0.29.
In the end, bioMérieux is an interesting title, but a little expensive, with a modest yield and a fairly slow growth rate. The dividend payment is nevertheless assured because it is well covered by the profit and the title is not very sensitive to market variations. bioMérieux therefore obtains 2 stars, i.e. an average profitability/risk ratio.
Sources: Wikipedia, Yahoo Finance, Swissquote, dividends.ch
Discover more from dividendes
Subscribe to get the latest posts sent to your email.
Français 
English 
Italiano 
Deutsch 
Español 
Português
Congratulations on your interesting site.
However, a question comes to mind every time, dividends are clearly ideal for the future rentier project but the amount of dividends becoming larger and larger and added to the income for taxes, it is far from the 100% of the dividend that we have in our pocket... and in our pocket we only have 65% because of the anticipated tax (recoverable). Basically on 1 chf of div, we actually receive 0.65 and then we pay tax on it because it is an income... how much is left in the end? (because on the one hand we pay the tax but we have the reduction linked to the reimbursement of the anticipated tax...). to summarize, my question is: on 1 chf of div, how much is actually left, taking everything into account?
An article on this subject would be very interesting.
greetings
chris
added my previous comment..
Is it worth selling the security on the ex-day and buying it back "at best" the next day at the opening? Doesn't that avoid tax (with the risk or chance that the security opens above or below its ex-div value)
There are those who buy before the ex date to capture the dividend and resell directly afterwards. There are those who sell before to avoid tax and buy back directly afterwards. These two strategies seem insane to me. Practicing in this way is wasting a lot of commissions unnecessarily. If it is to avoid tax, calculate what your marginal rate is and what it represents in CHF compared to the dividend, then calculate the commission compared to the sale and the purchase. Do you really think it is worth the effort?
Well it's very simple, and a whole article is not necessary. I take the example here of a Swiss title for a Swiss resident, i.e. a withholding tax of 35% on the dividend. On a dividend of CHF 100, this therefore represents CHF 35. Either you do not declare it, in which case this amount is lost, or you declare it and in which case it is the marginal tax rate that is authoritative, i.e. how much you will be taxed for having earned CHF 100 more than your income. This marginal rate depends on your family situation, your income and your location. You can calculate it using this link: https://apps1.ubs.com/financecalculator/ch/ft?ToolId=FAInternet&TargetComparId=BerechnungSteuernUndGrenzsteuersatz&LG=f&NavLB_Apps=1358120039.